PRDS Insider Trading Activity and SEC Form 4 Filings
PRDS insider trading summary
No open-market insider purchases or sales of Pardes Biosciences, Inc. (PRDS) have been reported on SEC Form 4 in the past 12 months.
Latest PRDS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 5, 2023 | Foresite Capital Opportunity Management V, LLC | 10% Owner | Buy | $1.2M (773,952 @ $1.50) |
| Apr 5, 2023 | Foresite Capital Opportunity Fund V, L.P. | 10% Owner | Buy | $1.2M (773,952 @ $1.50) |
| Apr 5, 2023 | James B. Tananbaum | Director | Buy | $1.2M (773,952 @ $1.50) |
| Apr 5, 2023 | James B. Tananbaum | Director | Buy | $1.2M (773,952 @ $1.50) |
| Apr 5, 2023 | Foresite Capital Fund V, L.P. | 10% Owner | Buy | $1.2M (773,952 @ $1.50) |
| Apr 5, 2023 | Foresite Capital Management V, LLC | 10% Owner | Buy | $1.2M (773,952 @ $1.50) |
| Dec 8, 2022 | Sean P. Brusky | Chief Commercial Officer | Buy | $25K (21,000 @ $1.19) |
| Dec 5, 2022 | Thomas G Wiggans | Chief Executive Officer | Buy | $14K (12,500 @ $1.09) |
| Dec 2, 2022 | Thomas G Wiggans | Chief Executive Officer | Buy | $13K (12,500 @ $1.07) |
| Dec 1, 2022 | Foresite Capital Management V, LLC | 10% Owner | Buy | $542K (637,420 @ $0.85) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.